Recap: VYNE Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
VYNE Therapeutics (NASDAQ:VYNE) reported Q3 earnings with an EPS of $-1.75, beating estimates by 11.17% but with a revenue decrease of $53 thousand from the previous year. Last quarter's EPS miss resulted in a 19.3% share price drop the following day.
November 13, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
VYNE Therapeutics reported better-than-expected Q3 earnings with an EPS of $-1.75, which was 11.17% higher than the estimated $-1.97. However, revenues fell slightly from the same period last year.
While VYNE Therapeutics exceeded earnings expectations, the decrease in revenue and the historical stock price drop after last quarter's earnings miss suggest a mixed reaction in the short term. The market may respond positively to the earnings beat, but the revenue decline and past performance could temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100